article thumbnail

2023 cancer research highlights: Drug development at its best

Drug Discovery World

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. million new cancer cases are expected to be diagnosed in the US in 2023”.

article thumbnail

Conversations from Cancer Research Horizons’ Innovation Summit 2023 

Drug Discovery World

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees.

Research 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DDW top reads in 2023

Drug Discovery World

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. Regulatory issues and diversity in clinical trials were also important in 2023, as well as the role that artificial intelligence tools like ChatGPT might play. This popular market report was featured in the Spring 2023 issue of DDW.

article thumbnail

Poster and award submissions open for Research & Innovation 2023

Drug Discovery World

The 2023 ELRIG Research & Innovation conference will take place on March 29-30. To be considered for a for a 10-minute oral presentation in the main scientific track, posters must be submitted by March 1, 2023. The deadline for general poster display at the event is March 19, 2023. .

Research 130
article thumbnail

Four breakthroughs in cancer research revealed at ASCO 2023

Drug Discovery World

Read more: Janssen updates ASCO 2023 on oncology pipeline NATALEE Phase III trial Data revealed at ASCO showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2% However, 29% of patients without the mutation also had an encouraging response.

Research 130
article thumbnail

Breakthrough drug discovery research collaboration in obesity

Drug Discovery World

Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023.

Research 147
article thumbnail

Meet the researcher: Jenny Hogstrom-Stakem

Drug Discovery World

Jenny Hogstrom-Stakem , Postdoctoral Research Fellow, was recently awarded the 2023 AACR-AstraZeneca Breast Cancer Research Fellowship. JHS : I’m a postdoctoral research fellow at Beth Israel Deaconess Medical Center/ Harvard Medical School doing breast cancer research.

Research 162